1526-83-6

Basic information

• Product Name: Perathiepin
• Synonyms: Perathiepin;Perathiepine;1-(5,6-dihydrobenzo[b][1]benzothiepin-6-yl)-4-methylpiperazine;1-(5,6-dihydrobenzo[b][1]benzothiepin-6-yl)-4-methyl-piperazine
• CAS NO: 1526-83-6
• Molecular Formula: C19H22N2S
• Molecular Weight: 310.463
• Mol File: 1526-83-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 415.4°Cat760mmHg
• Flash Point: 205°C
• Appearance: /
• Density: 1.169g/cm³
• Vapor Pressure: 4.13E-07mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: Perathiepin(CAS DataBase Reference)
• NIST Chemistry Reference: Perathiepin(1526-83-6)
• EPA Substance Registry System: Perathiepin(1526-83-6)

Safety Data

• Hazardous Substances Data: 1526-83-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C19H22N2S/c1-20-10-12-21(13-11-20)17-14-15-6-2-4-8-18(15)22-19-9-5-3-7-16(17)19/h2-9,17H,10-14H2,1H3

Upstream product

• 1898-85-7 dibenzo[b,f]thiepin-10(11H)-one 
• 22012-13-1 1-dibenzo[b,f]thiepin-10-yl-4-methyl-piperazine 
• 1527-17-9 2-[2-(phenylsulfanyl)phenyl]acetic acid 
• 18698-96-9 o-iodophenylacetic acid 
• 108-98-5 thiophenol 

Relevant articles and documents

Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents

Malaria remains a significant infectious disease with even artemisinin-based therapies now facing resistance in the field. Development of new therapies is urgently needed, either by finding new compounds with unique modes of action, or by reversing resistance towards known drugs with 'chemosensitizers' or 'chemoreversal' agents (CRA). Concerning the latter, we have focused on the resistance mechanisms developed against chloroquine (CQ). We have synthesized a series of compounds related to previously identified CRAs, and found promising novel compounds. These compounds show encouraging results in a coumarin labeled chloroquine uptake assay, exhibiting a dose response in resensitising parasites to the antimalarial effects of chloroquine. Selected compounds show consistent potency across a panel of chloroquine and artemisinin sensitive and resistant parasites, and a wide therapeutic window. This data supports further study of CRAs in the treatment of malaria and, ultimately, their use in chloroquine-based combination therapies.